Cedric Hermans/ institutroialbertdeux.be;
Jan Blatný/praguemorning.cz
Apr 1, 2026, 11:46
Cedric Hermans: Revisiting the Role of Factor VIII in Haemophilia A in 2026 on E-Learning Insights
Cedric Hermans, Head of Haemophilia Centre at the Saint-Luc University Hospital, Brussels, shared a post on LinkedIn:
“Revisiting the role of FVIII in Haemophilia A in 2026
In this episode, Cedric Hermans sits down with Jan Blatný, Consultant Haematologist at Masaryk University and University Hospital Brno, EHCC and EuroBloodNet Centre, and former EAHAD President (2024–2026), to explore the evolving role of Factor VIII in the management of haemophilia A in 2026.
As new therapies such as emicizumab, rebalancing agents, and gene therapy reshape the treatment landscape, this conversation revisits where FVIII remains essential.”
Stay updated with Hemostasis Today.
-
May 23, 2026, 03:02Maitri Vaishnav: Anatomical Variability and Surgical Relevance of Corona Mortis
-
May 23, 2026, 02:26Muhammad Hashim: When the Blood Smear Told a Different Story Behind a ‘Critical’ Platelet Count
-
May 23, 2026, 02:20Augustina Isioma Ikusemoro: Understanding One of the Most Common and Preventable Transfusion Reactions
-
May 23, 2026, 02:15What’s Your Advice for the Newly Diagnosed? – ITP Support Association
-
May 23, 2026, 02:08Rob Maloney: When You Stop Building Only a Career and Start Building a Life of Significance
-
May 23, 2026, 02:04Rahmathullah S.N.: Key Takeaways on Successful Surgical Outcomes in Patients with Congenital Bleeding Disorders
-
May 23, 2026, 01:51Paula Greter: Access and Innovation in Hemophilia through ERAH2026
-
May 22, 2026, 17:30Veronica Sanchez: Do You Live with Pain after a Stroke?
-
May 22, 2026, 17:25Maxime Dely: A Simple but Powerful Indicator of Platelet Quality